Skip to main content
Psybrary™

Synthetic Drug Candidates Available for Licensing

Explore the Psybrary Portfolios

Enveric boasts a rich repository of patented and patent-pending synthetic derivatives of the classic psychedelics N,N-dimethyltryptamine (DMT), psilocybin, and 3,4-methylenedioxymethamphetamine (MDMA).

57 of these novel molecules with unique receptor binding profiles and pharmacokinetic properties are available for out-licensing as potential drug candidates.

To the prospective partner, the molecules represent an opportunity for pipeline development and access to novel, protected compounds in a highly competitive and significant medical market.

For Enveric, the out-licensing made possible by the Psybrary™ Portfolios represents an opportunity to diversify risk while exploiting and retaining potential near term revenue streams across multiple drug candidates and markets.

Assets
# of Compounds
Receptor Binding
License Development

Bifunctional Psilocin Prodrug (BPP) Series

Learn More

5 Novel Compounds

5HT2A, 5HT1A, 5HT1B, SERT, GABA

In Discussions / Confidential

40%

Novel Serotonin-Norepinephrine-Dopamine Inhibitor (SNDRI) Series

Learn More

2 Novel Compounds

5HT1A, 5HT2A, SERT, DAT, NET

In Discussions / Confidential

40%

Melatonin Receptor Agonist (MRA) Series

Learn More

16 Novel Compounds

MT1, SERT, 5HT1A, 5HT1C, 5HT2A, 5HT2B, 5HT2C

In Discussions / Confidential

60%

Novel Antidepressant, NAD-01

Learn More

1 Novel Compound

5HT1A, SERT, 5HT2A

In Discussions / Confidential

60%

Novel MDMA Derivatives (EMD) Series

Learn More

20 Novel Compounds

SERT, 5HT1A, 5HT2A, 5HT2C, alpha2A, D3, DAT, NET

In Discussions / Confidential

40%

Novel Psilocin Prodrug (NPP) Series

Learn More

7 Novel Compounds

5HT2A

In Discussions / Confidential

40%

Novel Non-specific SRI (NSRI) Series

Learn More

6 Novel Compounds

SERT, 5HT1A, 5HT2A, D2L, D3

In Discussions / Confidential

40%